Undervalued Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Must Enter New Markets

Page 1 of 2

Generic producers are often regarded as the safer players within BioPharma. They take existing drugs that have fallen off patents, tweak them a bit, and release a product into the market. R&D expenses are kept low, and business is relatively predictable.

Similarly, medical device companies have lower risk profiles by virtue of their more predictable operating model. However, they both have experienced their own problems and are not resting on their laurels. To create value, they need to innovate and grow returns above the weighted average cost of capital. Below, I present my take on several companies within these two markets.

What Teva can gain from entering new markets

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been aggressively trying to shift away from its multiple sclerosis Copaxone, which makes up the bulk of its revenue. Its new $90 million plant in India recently began construction and is expected to produce consumer health-related products, which include inhalers, syrups, and other similar products. This new plant will operate under a local brand name of “Vicks” and should be completed by 2015. While relatively minor, it is a step in the right direction. Larger steps include the focus on executing a “pearl of strings acquisition” strategy akin to what the new CEO implemented over at Bristol-Myers.

The world’s largest generic producer should explore takeover activity in the medical device market to limit downside and shift towards greater predictability. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) should look towards adopting a more predictable business model by expanding into the medical device market. Failing to receive FDA approval for a drug versus a medical device product may mean the difference between having to start from scratch versus simply having to just follow-up on what works.

The medical device market also involves much less “shooting in the dark” than, say, the pharmaceutical market. And unlike many emerging firms, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s medical device division (“Teva Medical”) fortunately comes equipped with strong liquidity from a recognizable parent company. Why not use some of that $2.9 billion in cash to add obvious free cash flow generators? This would certainly take more of the attention off of patent cliffs by giving investors some “breathing room.”

Reasons to buy Teva irrespective of business shift

If nothing else, Teva has a lot to offer to defensive investors. It was recently named one of the top 10 companies in the Dividend Channel’s International S.A.F.E. 10 because of its current 2.90% dividend yield and a track-record of strong growth over the past five years. The S.A.F.E. status can only be achieved if all of the four marks –S for “solid return,” A for “accelerating amount,” F for “flawless 5-year track-record,” and E for “enduring”– come above average.

Ultimately, I remain very optimistic about Teva. The stock trades at only 7.3 times forward earnings and is more than 60% less volatile than the broader market. Free cash flow yield is strong at 7.3%, and the firm is expected to show 8.9% annual EPS growth over the next five years, which is relatively predictable. Combined with the dividend yield, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is a winning stock for defensive investors.

Will Mylan Inc. (NASDAQ:MYL) continue to soar?

Mylan Inc. (NASDAQ:MYL) is yet another company that has had difficulties but managed to correct them. Operational scaling — like expanding internationally by opening a new arm in Ireland — has strengthened upside prospects. The result is that the generic manufacturer has been on a relentless 50%+ rise to its 52-week high. Thus, it too provides a perfect case study for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) turnaround executives.

The company has, however, run into its share of problems. The company is now facing a lawsuit from Santarus, which filed a patent infringement lawsuit for its Fenoglide tablets product. The reason for this lawsuit was the ANDA Mylan signed to create generic versions of Santarus’ product, but Fenoglide is still under a patent protection until 2024.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!